FibroGen Report Enrollment of First Patient in P-II Study Evaluating Pamrevlumab in Patients Hospitalized with Acute COVID-19

 FibroGen Report Enrollment of First Patient in P-II Study Evaluating Pamrevlumab in Patients Hospitalized with Acute COVID-19

Shots:

  • FibroGen initiates the P-II study assessing the efficacy and safety of pamrevlumab vs SOC in hospitalized patients in a ratio (1:1) with acute COVID-19 across the US and is expected to enroll ~130 patients
  • The focus of the study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 with 1EPs as the proportion of hospitalized patients who have not received mechanical ventilation and ECMO and remain alive at day 28
  • The company is expected to evaluate the longer-term efficacy and safety of pamrevlumab in patients who have recovered or are recovering from COVID-19 with evidence of interstitial lung disease in the second clinical study to be conducted in the US

Click here to read full press release/ article | Ref: PRNewswire | Image: Fibrogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post